EUVIMEDEUVIMED entdecken
Open Access

Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes

Helena Neudorf iD, Hashim Islam, Kaja Falkenhain iD, Barbara Oliveira, Garett S Jackson, Alfonso Moreno-Cabañas, Kenneth Madden, Joel Singer, Jeremy J Walsh, Jonathan P Little

Clinical and Experimental Immunology · 2024

DOI: 10.1093/cei/uxad138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Immunology, 2024. Verfasst von Helena Neudorf und 9 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia Okanagan, School of Health and Exercise Sciences, Kelowna, BC, Canada. Hauptthemen laut MEDLINE: Interleukin-10, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canadian Institutes of Health Research, Natural Sciences and Engineering Research Council of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pre-clinical and cell culture evidence supports the role of the ketone beta-hydroxybutyrate (BHB) as an immunomodulatory molecule that may inhibit inflammatory signalling involved in several chronic diseases such as type 2 diabetes (T2D), but studies in humans are lacking. Therefore, we investigated the anti-inflammatory effect of BHB in humans across three clinical trials. To investigate if BHB suppressed pro-inflammatory cytokine secretion, we treated LPS-stimulated leukocytes from overnight-fasted adults at risk for T2D with BHB (Study 1). Next (Study 2), we investigated if exogenously raising BHB acutely in vivo by ketone monoester supplementation (KME) in adults with T2D would suppress pro-inflammatory plasma cytokines. In Study 3, we investigated the effect of BHB on inflammation via ex vivo treatment of LPS-stimulated leukocytes with BHB and in vivo thrice-daily pre-meal KME for 14 days in adults with T2D. Ex vivo treatment with BHB suppressed LPS-stimulated IL-1β, TNF-α, and IL-6 secretion and increased IL-1RA and IL-10 (Study 1). Plasma IL-10 increased by 90 min following ingestion of a single dose of KME in T2D, which corresponded to peak blood BHB (Study 2). Finally, 14 days of thrice-daily KME ingestion did not significantly alter plasma cytokines or leukocyte subsets including monocyte and T-cell polarization (Study 3). However, direct treatment of leukocytes with BHB modulated TNF-α, IL-1β, IFN-γ, and MCP-1 secretion in a time- and glucose-dependent manner (Study 3). Therefore, BHB appears to be anti-inflammatory in T2D, but this effect is transient and is modulated by the presence of disease, glycaemia, and exposure time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-10Diabetes Mellitus, Type 2AdultHumans3-Hydroxybutyric AcidKetonesTumor Necrosis Factor-alphaLipopolysaccharidesInflammationCytokinesAnti-Inflammatory AgentsInterleukin-1betaImmunity

Stichwörter der Autor:innen

beta-hydroxybutyratecytokinesketonestype 2 diabetes

Substanzen

3-Hydroxybutyric AcidInterleukin-10KetonesTumor Necrosis Factor-alphaLipopolysaccharidesCytokinesAnti-Inflammatory AgentsInterleukin-1beta

Autor:innen und Institutionen

  • University of British Columbia Okanagan, School of Health and Exercise Sciences, Kelowna, BC, Canada.
  • University of Castilla-La Mancha, Department of Sport Sciences, Exercise Physiology Lab at Toledo, Spain.
  • University of British Columbia, Department of Medicine, Centre of Aging SMART, Vancouver, BC, Canada.
  • University of British Columbia, School of Population and Public Health, Vancouver, BC,Canada.
  • McMaster University, Department of Kinesiology, Hamilton, ON, Canada.

ORCID-Profile: Helena Neudorf, Kaja Falkenhain

Förderung

  • CIHR
  • Canadian Institutes of Health Research
  • Natural Sciences and Engineering Research Council of Canada
  • Michael Smith Foundation for Health Research

Zitieren

APA

Neudorf, H., Islam, H., Falkenhain, K., Oliveira, B., Jackson, G. S., Moreno-Cabañas, A., Madden, K., Singer, J., Walsh, J. J., & Little, J. P. (2024). Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxad138

Vancouver

Neudorf H, Islam H, Falkenhain K, Oliveira B, Jackson GS, Moreno-Cabañas A, et al. Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes. Clinical and Experimental Immunology. 2024. doi:10.1093/cei/uxad138

BibTeX
@article{Neudorf2024,
  author = {Neudorf, Helena and Islam, Hashim and Falkenhain, Kaja and Oliveira, Barbara and Jackson, Garett S and Moreno-Cabañas, Alfonso and Madden, Kenneth and Singer, Joel and Walsh, Jeremy J and Little, Jonathan P},
  title = {Effect of the ketone beta-hydroxybutyrate on markers of inflammation and immune function in adults with type 2 diabetes},
  journal = {Clinical and Experimental Immunology},
  year = {2024},
  doi = {10.1093/cei/uxad138}
}
Kostenlos starten →